HAVCR2 and neoplasm: Previous studies have shown that blockade of TIM-3 in conjunction with PD-1 inhibition may suppress tumor progression in preclinical models and contribute to anti-tumor immune responses in several malignancies, thus supporting the development of TIM-3-based immunotherapeutic approaches [13].